MedPath

Cema-cel Shows Promising 2-Year Durability Data in Large B-Cell Lymphoma Treatment

• Allogene Therapeutics' cema-cel demonstrates sustained efficacy with 23.1-month median response duration in relapsed/refractory large B-cell lymphoma patients from ALPHA trials.

• The allogeneic CAR T-cell therapy achieves remarkable complete response rates in first-line consolidation treatment for patients with low disease burden.

• Long-term follow-up data reinforces cema-cel's safety profile and therapeutic potential as an off-the-shelf treatment option for lymphoma patients.

Groundbreaking two-year follow-up data from the ALPHA clinical trials has reinforced the therapeutic potential of cemacabtagene ansegedleucel (cema-cel) in treating relapsed/refractory large B-cell lymphoma. The allogeneic CAR T-cell therapy, developed by Allogene Therapeutics, demonstrated remarkable durability with a median response duration of 23.1 months among 33 CAR T-naive patients.

Clinical Trial Outcomes and Significance

The combined results from the phase 1 ALPHA (NCT03939026) and ALPHA2 (NCT04416984) trials revealed impressive efficacy metrics, with overall survival not yet reached at the two-year mark. These findings represent the longest follow-up data available for this innovative treatment approach.
Building on these promising results, the ongoing ALPHA3 trial (NCT06500273) has achieved a 100% complete response rate when using cema-cel as consolidation treatment in first-line therapy for patients with low disease burden.

Understanding CAR T-Cell Therapy Approaches

Dr. Frederick L. Locke, Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center and Research Institute, explains the fundamental differences between autologous and allogeneic CAR T-cell therapies.
"CAR T-cell therapy works by taking out the body's T cells," Dr. Locke explains. "These are immune cells that help recognize infections or infected cells within the body." In traditional autologous approaches, patients' own T cells are extracted and genetically modified with a chimeric antigen receptor (CAR) to target specific proteins, such as CD19, on cancer cells.

Advantages of Allogeneic Approach

The allogeneic approach utilized by cema-cel differs by employing T cells from healthy donors instead of patient-derived cells. This "off-the-shelf" approach potentially offers several advantages, though it requires careful management to prevent rejection and graft-versus-host disease.
The therapy works by reprogramming these donor T cells to recognize and destroy cancerous B cells bearing specific surface proteins. Once infused intravenously, these modified cells circulate throughout the body, actively seeking and eliminating cancer cells.

Clinical Implementation and Future Directions

The robust durability data from the ALPHA trials suggests that cema-cel could represent a significant advancement in lymphoma treatment. The therapy's success in both relapsed/refractory settings and as first-line consolidation treatment indicates its potential versatility across different treatment stages.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Allogene's CAR T-Cell Therapy Shows Promising Results in Large B-Cell Lymphoma Trials

Phase 1 ALPHA and ALPHA2 trials demonstrate cemacabtagene ansegedleucel achieves 67% overall response rate and 58% complete response rate in relapsed/refractory LBCL patients using the selected Phase 2 regimen.
The therapy shows a manageable safety profile with no graft-versus-host disease or high-grade cytokine release syndrome, comparable to approved autologous CAR T-cell treatments.

Stanford Study Reveals Origins of Post-CAR-T Myeloid Neoplasms, Suggesting Similarities to Known Treatment-Related Malignancies

Stanford researchers analyzed 17 cases of post-CAR-T myeloid neoplasms, finding patterns similar to post-autologous transplant malignancies with strong associations to TP53 mutations.
The study revealed that most myeloid neoplasms developed from pre-existing clonal hematopoiesis, particularly in patients who received multiple cellular therapies.

Large-Scale Study Confirms Safety of CAR T-Cell Therapy: No Link to Secondary Cancers Found

A comprehensive study of 783 patients published in Nature Medicine found no evidence that CAR T-cell therapy causes secondary cancers through insertional mutagenesis.
Researchers identified 18 cases of secondary cancers post-treatment, attributing them to prior chemotherapy and radiation rather than CAR T-cell therapy itself.

Novel Discovery: CAR Molecules Can Transfer Between T Cells in Cancer Immunotherapy

Uppsala University researchers have discovered that CAR molecules can transfer from engineered CAR-T cells to other T cells through a process called trogocytosis, challenging previous understanding of this mechanism.
The study reveals that molecule transfer depends on the membrane region surrounding the cell surface molecule, rather than requiring specific receptor-binding partnerships between cells.

Dual-Target CAR T-Cell Therapy Shows Promise in Pediatric Leukemia Trial

A Phase 1 trial at Children’s Hospital Colorado is evaluating a novel CAR T-cell therapy targeting both CD19 and CD22 proteins in relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
The CD19x22 CAR T-cell therapy aims to improve remission rates and prevent relapse by addressing the loss of CD19 protein, a common resistance mechanism.

CAR T-Cell Therapy Shows Promise Beyond Cancer in Treating Lupus

Early results from a small study indicate that CAR T-cell therapy may be effective in treating lupus, an autoimmune disease driven by B cells.
Researchers are optimistic about the potential for CAR T therapies to be applied to a wider range of conditions beyond B cell cancers.

CAR T-Cell Therapy Shows Promise Beyond Cancer in Treating Lupus

Early results indicate CAR T-cell therapy may be effective in treating autoimmune diseases like lupus by targeting B cells.
Researchers are optimistic about CAR T therapies' potential beyond cancer, with lupus being a prime target due to its B-cell-driven nature.

Carvykti Approved for Relapsed/Refractory Multiple Myeloma After Multiple Lines of Therapy

The FDA approved ciltacabtagene autoleucel (Carvykti) for multiple myeloma patients who have relapsed or are refractory after multiple lines of therapy.
Carvykti, a CAR T-cell therapy targeting BCMA, demonstrated high response rates in clinical trials, offering a new treatment option for heavily pre-treated patients.

CAR T-cell Therapy Shows Promise in Treating B-cell Lymphoma

Recent studies highlight the effectiveness of CAR T-cell therapy in treating aggressive B-cell lymphoma, with significant response rates and manageable adverse events. Real-world data and long-term follow-ups support its use, despite challenges like cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

Advancements in CAR-Modified T Cells for Leukemia Treatment

Recent developments in cellular immunotherapy have introduced CAR-modified T cells targeting the CD19 antigen as a promising strategy for treating B-cell cancers. Despite challenges in clinical trial design and CAR structure, early trials show potential for significant impact on disease progression.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy